281 related articles for article (PubMed ID: 7564332)
1. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Morita O; Kushida H; Kunihara M
J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
[TBL] [Abstract][Full Text] [Related]
2. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
Bunting MW; Widdop RE
Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
[TBL] [Abstract][Full Text] [Related]
3. Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats.
Toney GM; Porter JP
Brain Res Dev Brain Res; 1993 Feb; 71(2):193-9. PubMed ID: 8491041
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats.
Widdop RE; Gardiner SM; Bennett T
Brain Res; 1994 Jun; 648(1):46-52. PubMed ID: 7922526
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174.
Widdop RE; Gardiner SM; Kemp PA; Bennett T
Br J Pharmacol; 1992 Nov; 107(3):873-80. PubMed ID: 1472980
[TBL] [Abstract][Full Text] [Related]
6. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats.
Toney GM; Porter JP
Neuropharmacology; 1993 Jun; 32(6):581-9. PubMed ID: 8336821
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
8. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin.
Hogarty DC; Speakman EA; Puig V; Phillips MI
Brain Res; 1992 Jul; 586(2):289-94. PubMed ID: 1521162
[TBL] [Abstract][Full Text] [Related]
9. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.
Gorbea-Oppliger VJ; Melaragno MG; Potter GS; Petit RL; Fink GD
J Pharmacol Exp Ther; 1994 Nov; 271(2):804-10. PubMed ID: 7965799
[TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat.
Junggren IL; Zhao X; Sun X; Hedner T
J Pharm Pharmacol; 1996 Aug; 48(8):829-33. PubMed ID: 8887734
[TBL] [Abstract][Full Text] [Related]
11. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
[TBL] [Abstract][Full Text] [Related]
14. Functional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response.
Toney GM; Porter JP
Brain Res; 1993 Feb; 603(1):57-63. PubMed ID: 8453478
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist.
Nagura J; Yasuda S; Fujishima K; Yamamoto M; Hui C; Kawano K; Katano K; Ogino H; Hachisu M; Konno F
Eur J Pharmacol; 1995 Feb; 274(1-3):201-11. PubMed ID: 7768273
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype.
Wong PC; Quan ML; Saye JM; Bernard R; Crain EJ; McCall DE; Watson CA; Zaspel AM; Smith RD; Wexler RR
J Cardiovasc Pharmacol; 1995 Sep; 26(3):354-62. PubMed ID: 8583775
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
Kivlighn SD; Zingaro GJ; Gabel RA; Broten TP; Schorn TW; Schaffer LW; Naylor EM; Chakravarty PK; Patchett AA; Greenlee WJ
Am J Hypertens; 1995 Jan; 8(1):58-66. PubMed ID: 7734099
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
Tamura K; Okuhira M; Amano H; Inokuma K; Hirata T; Mikoshiba I; Hashimoto K
J Cardiovasc Pharmacol; 1997 Nov; 30(5):607-15. PubMed ID: 9388043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
